Business Context and Reporting Period
This Form 8-K Current Report was filed by Lifemd, Inc. on April 26, 2024. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
The material change reported is the appointment of Calum MacRae to the Board of Directors on April 26, 2024. Dr. MacRae brings significant medical and scientific credentials, including serving as Vice Chair for Scientific Innovation at Brigham and Women's Hospital and as a faculty member at Harvard Medical School since 2002.
Compensatory Arrangements and Agreements
In connection with his appointment, Dr. MacRae entered into a Director Agreement and a Restricted Stock Award Agreement. The compensation package includes:
- Total Grant: 50,000 restricted shares of common stock under the LifeMD, Inc. 2020 Equity and Incentive Plan.
- Vesting Schedule:
- 16,500 shares granted April 26, 2024, vesting April 26, 2025.
- 16,500 shares granted April 26, 2025, vesting April 26, 2026.
- 17,000 shares granted April 26, 2026, vesting April 26, 2027.
- Acceleration Clauses: Unvested shares vest immediately if Dr. MacRae is removed or not re-elected for reasons other than "Cause," or immediately prior to a "Change of Control."
- Forfeiture: Awards may be forfeited upon breach of certain covenants.
Investor Verification Checklist
- Verify the full text of the Director Agreement (Exhibit 10.1) and Restricted Stock Award Agreement (Exhibit 10.2) for specific definitions of "Cause" and "Change of Control."
- Review the press release dated April 29, 2024 (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
- Confirm the impact of the 50,000 share grant on total outstanding shares and potential dilution in subsequent filings.